Food and Drug Administration (FDA) has approved Biotronik's implantable cardioverter defibrillator (ICD) that is capable of producing an ultra-high energy electrical shock immediately on the first discharge.
Biotronik is the leading manufacturer of cardiovascular medical technology. According to the company, defibrillators have capacitors within them that store an electrical charge that is originally siphoned from a nearby battery.
Unlike previous high energy ICDs, the new Inventra DX ICD stays completely vigilant and is able to fire off 42 Joules of energy at any moment. The device uses only one lead that is capable of dual-chamber diagnostics, offering extra safety compared with using two leads while offering comparable continuous heart monitoring.
Experts in the field of electrophysiology have indicated that meaningful therapeutic innovations available in the ICDs - like high energy options, DX systems and CLS - make it easier for physicians to tailor therapy and improve the quality of life for their patients.
"This approval is yet another example of our company's ability to offer unique stand-alone technology to support electrophysiologists as they pursue their life-saving, life-changing work for patients," said Marlou Janssen, President, BIOTRONIK, Inc.